We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer ( BC ) to evaluate progression-free survival ( PFS ) for nab-paclitaxel or ixabepilone versus paclitaxel .